Probi announces changed dividend policy effective 2016 financial year

In conjunction with today’s publication of the Probi annual report for 2015, a changed dividend policy was presented, which has been decided by the company’s Board of Directors.

The Board of Directors of Probi AB (publ) has reviewed and decided to change the company’s dividend policy with effect from the 2016 financial year:

Previous dividend policy:
Assuming that Probi is able to maintain a suitable capital structure in the future, and that it is deemed possible to maintain the company´s financial objectives, Probi’s goal is to pay a dividend of 30-50% of profit after tax.

New dividend policy:
In future, the dividend will be based on Probi’s earnings level and financial position, as well as requirements for the financing of investment opportunities. On an annual basis, the Board will evaluate the potential to pay a dividend and, in so doing, will balance the shareholders’ expectations of a reasonable dividend yield with the company’s needs to self-finance its continued growth and expansion.

Probi’s annual report for 2015 is now available on the company’s website. The printed version is scheduled to be distributed during the week beginning 11 April to those shareholders who subscribe to financial reports from Probi.


This information is subject to statutory disclosure requirements in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.

FOR MORE INFORMATION, PLEASE CONTACT:
Peter Nählstedt, CEO, Probi, tel: +46 46 286 23 23 or mob: +46 723 723 99 83 83, or e-mail: peter.nahlstedt@probi.se
Niklas Brandt, CFO, Probi, tel +46 46 286 89 26 eller mobil +46 706 62 98 83, e-post: niklas.brandt@probi.se

ABOUT PROBI
Probi AB is a publicly traded Swedish bioengineering company that develops effective and well-documented probiotic products. Probi has created a strong product portfolio in the gastrointestinal health and immune system niches based on its world-leading research. Probi’s products are available to consumers in more than 30 countries throughout the world. Probi’s customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. During 2015, Probi’s sales amounted to MSEK 216. Probi’s share is listed on Nasdaq OMX Stockholm, Small Cap. Probi has approximately 3,500 shareholders. For further information, please visit www.probi.se.

Tags:

About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.

Contacts

Subscribe

Documents & Links